Mercados españoles cerrados

Denali Therapeutics Inc. (DNLI)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD
Añadir a la lista de favoritos
20,52-0,25 (-1,20%)
Al cierre: 04:00PM EDT
20,54 +0,02 (+0,08%)
Después del cierre: 06:17PM EDT

Denali Therapeutics Inc.

161 Oyster Point Boulevard
South San Francisco, CA 94080
United States
650-866-8548
https://www.denalitherapeutics.com

Sector(es)Healthcare
SectorBiotechnology
Empleados a tiempo completo445

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Dr. Ryan J. Watts Ph.D.Co-Founder, President, CEO & Director1,04M2,17M1976
Dr. Alexander O. Schuth M.D.Co-Founder, CFO, COO & Secretary737,2k601,4k1973
Dr. Marc Tessier-Lavigne Ph.D.Co-Founder & Independent Director58,23kN/A1960
Dr. Carole Ho M.D.Chief Medical Officer & Head of Development737,2kN/A1973
Mr. Tyler M. NielsenSenior Vice President of Corporate FinanceN/AN/A1978
Dr. Dana AndersenChief Technical and Manufacturing OfficerN/AN/AN/A
Mr. Joe Lewcock Ph.D.Chief Scientific OfficerN/AN/AN/A
Dr. Laura HansenVice President of Investor RelationsN/AN/AN/A
Mr. Chris WalshGeneral CounselN/AN/AN/A
Mr. Mark RowenVice President of Corporate DevelopmentN/AN/AN/A
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Gobierno corporativo

El ISS Governance QualityScore de Denali Therapeutics Inc., a día 1 de marzo de 2024, es 6. Las puntuaciones base son Auditoría: 1; Tablero: 4; Derechos de los accionistas: 8; Compensación: 9.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.